Options to clinically address obesity

A number of key events are likely to take place during the 2011-2019 forecast period that will serve to determine the size and course of various segments of the market for products in the clinical management of obesity. We have projected their occurrence (or not), and likely impact, following extensive industry participant interviews, our knowledge of the market approval processes in the various countries and regions, advantages and disadvantages of the various products as derived from clinical trial reports, and observations regarding the apparent attitude of the US FDA in 2010 when it comes to reviewing anti-obesity drugs for marketing in the USA.

  • Drugs
    • Satiety
    • Malabsorption
    • Appetite suppression
    • Combination drugs
  • Medical devices
    • Restrictive
    • Artificial fullness
    • Malabsorption
    • Gastric emptying
    • Appetite suppression

From a surgical perspective, which may or may not involve the use of an accompanying device, the options are:

  • Gastric bypass, including a variation known as vertical banded gastroplasty (VBG); the latter is both malabsorptive and restrictive.
  • Roux-en-Y (vertical division)
  • Sleeve gastrectomy independent of biliopancreatic diversion.
  • Biliopancreatic diversion with duodenal switch (both malabsorptive and restrictive)
  • Gastric banding (restrictive)

These may be performed using either open surgery or laparoscopically, but are usually done via laparoscope.


For more information, see Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”